Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Immune checkpoint inhibitor (ICI) therapy targeting anti-programmed cell death-1 (anti-PD-
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …
1) or its ligand (anti-PD-L1) is the backbone of numerous combination regimens aimed at …
[PDF][PDF] Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
worldwide.(1, 2) This neoplasm has some unique characteristics. It occurs in most cases …
Breakthroughs in hepatocellular carcinoma therapies
Several breakthroughs in hepatocellular carcinoma (HCC) therapy across tumor stages
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …
provide hope to improve its dismal prognosis. Although surgical and local ablative therapies …
[HTML][HTML] Real-world data on the diagnosis, treatment, and management of hepatocellular carcinoma in the Asia-Pacific: the INSIGHT study
YK Sim, MC Chong, M Gandhi, YM Pokharkar, Y Zhu… - Liver Cancer, 2024 - karger.com
Introduction: Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer
and the third leading cause of cancer death worldwide. While there has been rapid evolution …
and the third leading cause of cancer death worldwide. While there has been rapid evolution …
Portal vein tumor thrombosis and hepatocellular carcinoma–the changing tides
AR Khan, X Wei, X Xu - Journal of Hepatocellular Carcinoma, 2021 - Taylor & Francis
Portal vein involvement is considered one of the most fearful complications of hepatocellular
carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor …
carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor …
Artificial intelligence in precision medicine in hepatology
The advancement of investigation tools and electronic health records (EHR) enables a
paradigm shift from guideline‐specific therapy toward patient‐specific precision medicine …
paradigm shift from guideline‐specific therapy toward patient‐specific precision medicine …
The role of IGF/IGF-1R signaling in hepatocellular carcinomas: stemness-related properties and drug resistance
MHT Ngo, HY Jeng, YC Kuo, JD Nanda… - International journal of …, 2021 - mdpi.com
Insulin-like Growth Factor (IGF)/IGF-1 Receptor (IGF-1R) signaling is known to regulate stem
cell pluripotency and differentiation to trigger cell proliferation, organ development, and …
cell pluripotency and differentiation to trigger cell proliferation, organ development, and …
[PDF][PDF] Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading
cause of cancer‐related deaths worldwide. Sarcomatoid HCC is a rare histological subtype …
cause of cancer‐related deaths worldwide. Sarcomatoid HCC is a rare histological subtype …
Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on …
X Zou, Q Xu, R You, G Yin - Cancer Medicine, 2023 - Wiley Online Library
Background Although the appearance of portal vein tumor thrombus (PVTT) is significantly
associated with unfavorable prognosis, there is insufficient evidence to confirm the efficacy …
associated with unfavorable prognosis, there is insufficient evidence to confirm the efficacy …
Paradigm shift in the treatment options of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is prevalent worldwide with suboptimal therapeutic
outcomes. The advancement of therapeutic options and the development of new systemic …
outcomes. The advancement of therapeutic options and the development of new systemic …